|
|
|
|
||
Re: BMO $IONS Risdiplam approval remains a headline risk for IONS shares,but expect less active switching from Spinraza at launch, compared to consensus, as historically physicians are less likely to switch out a working therapy.restricted label for RisdiYou don't need to see "active switching from Spinraza" for this drug to be a significant negative for IONS. Just a significant number of new cases choosing this drug over Spinraza would be enough for IONS stock to take a hit IMO. I don't know if that will happen. There are a lot of questions in my mind about this drug but the market reaction indicates that a lot of people think the drug has merit. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
61331 | Re: BMO $IONS Risdiplam approval remains a headline risk for IONS shares,but expect less active switching from Spinraza at launch, compared to consensus, as historically physicians are less likely to switch out a working therapy.restricted label for Risdi | arthurs1 | 1 | 2/15/2020 4:23:42 PM |